Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer

Tumori. Jul-Aug 2014;100(4):370-6. doi: 10.1700/1636.17888.

Abstract

The identification of clinical, biochemical and molecular markers to predict or monitor the efficacy of bevacizumab represents a major point in the treatment of patients with metastatic colorectal cancer. Studies and genetic analyses have been conducted to identify a predictive biomarker of bevacizumab efficacy. However, genes of the angiogenic pathway and angiogenic biomarkers vary substantially, thereby causing interindividual differences that complicate the identification of predictors for anti-vascular endothelial growth factor drugs like bevacizumab. So, the current challenge in bevacizumab treatment is to find predictive markers and implement them in clinical practice. In this review we have summarized the potential candidate biomarkers that may have a role in identifying patients who benefit most from bevacizumab treatment.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / adverse effects
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Bevacizumab
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / pathology*
  • Drug Eruptions / etiology
  • Endothelial Progenitor Cells
  • Genes, ras
  • Humans
  • Hypertension / chemically induced
  • Mutation
  • Neovascularization, Pathologic / drug therapy*
  • Obesity / complications
  • Predictive Value of Tests
  • Proto-Oncogene Proteins B-raf / genetics
  • Transcriptome
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*
  • Vascular Endothelial Growth Factor A / blood

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf